+

WO1999030157A3 - Neuropilines et leur utilisation a des fins de diagnostic et de pronostic du cancer - Google Patents

Neuropilines et leur utilisation a des fins de diagnostic et de pronostic du cancer Download PDF

Info

Publication number
WO1999030157A3
WO1999030157A3 PCT/US1998/026127 US9826127W WO9930157A3 WO 1999030157 A3 WO1999030157 A3 WO 1999030157A3 US 9826127 W US9826127 W US 9826127W WO 9930157 A3 WO9930157 A3 WO 9930157A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuropilins
prognosis
diagnosis
cancer
methods
Prior art date
Application number
PCT/US1998/026127
Other languages
English (en)
Other versions
WO1999030157A9 (fr
WO1999030157A2 (fr
Inventor
Michael Klagsbrun
Shay Soker
Hua-Quan Miao
Seiji Takashima
Original Assignee
Childrens Medical Center
Michael Klagsbrun
Shay Soker
Miao Hua Quan
Seiji Takashima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Michael Klagsbrun, Shay Soker, Miao Hua Quan, Seiji Takashima filed Critical Childrens Medical Center
Priority to AU18108/99A priority Critical patent/AU1810899A/en
Publication of WO1999030157A2 publication Critical patent/WO1999030157A2/fr
Publication of WO1999030157A3 publication Critical patent/WO1999030157A3/fr
Publication of WO1999030157A9 publication Critical patent/WO1999030157A9/fr
Priority to US09/583,638 priority patent/US6635421B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des récepteurs du facteur de croissance de l'endothélium vasculaire (VEGFR), et des neuropilines telles que les VEGF165R/NP-1 et NP-2 qui sont associées au potentiel métastatique des cellules malignes, et sur leur utilisation pour diagnostiquer ou pronostiquer le cancer. Les neuropilines VEGF165R/NP-1 et NP-2 sont préférées, mais toute neuropiline ou tout VEGFR dont les constituants présentent 85 % d'homologie avec lesdites VEGF165R/NP-1 et NP-2, ou mieux 90 %, ou mieux encore 95 %, peut être utilisé.
PCT/US1998/026127 1997-12-09 1998-12-09 Neuropilines et leur utilisation a des fins de diagnostic et de pronostic du cancer WO1999030157A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU18108/99A AU1810899A (en) 1997-12-09 1998-12-09 Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
US09/583,638 US6635421B1 (en) 1997-12-09 2000-05-30 Neuropilins and use thereof in methods for diagnosis and prognosis of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6915597P 1997-12-09 1997-12-09
US6968797P 1997-12-12 1997-12-12
US60/069,155 1997-12-12
US60/069,687 1997-12-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/583,638 Continuation US6635421B1 (en) 1997-12-09 2000-05-30 Neuropilins and use thereof in methods for diagnosis and prognosis of cancer

Publications (3)

Publication Number Publication Date
WO1999030157A2 WO1999030157A2 (fr) 1999-06-17
WO1999030157A3 true WO1999030157A3 (fr) 1999-07-22
WO1999030157A9 WO1999030157A9 (fr) 1999-10-21

Family

ID=26749747

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1998/026103 WO1999029861A1 (fr) 1997-12-09 1998-12-09 Peptides antagonistes du facteur de croissance de l'endothelium vasculaire
PCT/US1998/026127 WO1999030157A2 (fr) 1997-12-09 1998-12-09 Neuropilines et leur utilisation a des fins de diagnostic et de pronostic du cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1998/026103 WO1999029861A1 (fr) 1997-12-09 1998-12-09 Peptides antagonistes du facteur de croissance de l'endothelium vasculaire

Country Status (5)

Country Link
EP (1) EP1037994A1 (fr)
JP (2) JP4312955B2 (fr)
AU (2) AU1810899A (fr)
CA (1) CA2313390A1 (fr)
WO (2) WO1999029861A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6635421B1 (en) * 1997-12-09 2003-10-21 Children's Medical Center Corporation Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
AU783683B2 (en) * 2000-01-18 2005-11-24 Vegenics Limited VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
JP4981229B2 (ja) 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
CA2410887C (fr) 2000-06-02 2012-07-24 Bracco Research Usa Composes pour le ciblage des cellules endotheliales, compositions les contenant et leurs procedes d'utilisation
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
AU8591901A (en) * 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
GB0029015D0 (en) 2000-11-28 2001-01-10 Univ London Medical device
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
GB0207644D0 (en) * 2002-04-02 2002-05-15 Ark Therapeutics Ltd Peptides and their use
PL2949658T3 (pl) 2003-03-03 2018-11-30 Dyax Corp. PEPTYDY SPECYFICZNIE WIĄŻĄCE SIĘ Z RECEPTOREM HGF (cMET) I ICH ZASTOSOWANIA
MX2008001966A (es) * 2005-08-12 2008-03-26 Regeneron Pharma Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf.
WO2007022287A2 (fr) 2005-08-15 2007-02-22 Vegenics Limited Vegf-a modifié aux propriétés angiogéniques améliorées
KR20080073711A (ko) * 2005-10-21 2008-08-11 바이엘 헬스케어 엘엘씨 암의 예측 및 예후 방법, 및 암 치료 모니터링 방법
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
DK2524693T3 (da) * 2010-01-14 2014-08-25 Sanwa Kagaku Kenkyusho Co Lægemiddel til forebyggelse eller behandling af lidelser ledsaget af okulær angiogenese og / eller forøget okulær vaskulær permeabilitet
BR112013000340A2 (pt) 2010-07-09 2016-05-31 Genentech Inc anticorpo isolado que se liga a neuropilina-1 (nrp1), ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado e método de detecção da presença de nrp1 em uma amostra biológica
US11505610B2 (en) 2018-04-06 2022-11-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
AU2020358854A1 (en) 2019-10-03 2022-05-26 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011499A1 (fr) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 UTILISE COMME RECEPTEUR POUR FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE
WO1997008313A1 (fr) * 1995-08-25 1997-03-06 Genentech, Inc. Variants du facteur de croissance des cellules de l'endothelium vasculaire, leurs utilisations et leurs procedes de fabrication

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011499A1 (fr) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 UTILISE COMME RECEPTEUR POUR FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE
WO1997008313A1 (fr) * 1995-08-25 1997-03-06 Genentech, Inc. Variants du facteur de croissance des cellules de l'endothelium vasculaire, leurs utilisations et leurs procedes de fabrication

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. L. KOLODKIN ET AL.: "Neuropilin is a semaphorin III receptor.", CELL, vol. 90, 22 August 1997 (1997-08-22), pages 753 - 762, XP002084496 *
H. CHEN ET AL.: "Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins sema E and sema IV but not sema III.", NEURON, vol. 19, September 1997 (1997-09-01), pages 547 - 559, XP002084494 *
S. SOKER ET AL.: "Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5761 - 5767, XP002097905 *
S. SOKER ET AL.: "Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.", CELL, vol. 92, 20 March 1998 (1998-03-20), pages 735 - 745, XP002097906 *
T. OMURA ET AL.: "Identification of a 190-kDa vascular endothelial growth factor 165 cell surface binding protein on a human glioma cell line.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 37, 12 September 1997 (1997-09-12), pages 23317 - 23322, XP002097907 *

Also Published As

Publication number Publication date
CA2313390A1 (fr) 1999-06-17
WO1999030157A9 (fr) 1999-10-21
WO1999029861A1 (fr) 1999-06-17
WO1999030157A2 (fr) 1999-06-17
JP4312955B2 (ja) 2009-08-12
JP2009148293A (ja) 2009-07-09
AU1810899A (en) 1999-06-28
AU1906099A (en) 1999-06-28
EP1037994A1 (fr) 2000-09-27
JP2001526032A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
WO1999030157A3 (fr) Neuropilines et leur utilisation a des fins de diagnostic et de pronostic du cancer
EP1746160A3 (fr) Antagonistes du récepteur du facteur de croissance des hepatocytes et leurs utilisations
EP0916635A3 (fr) Revêtements céramiques à porosité stratifiée
CA2258153A1 (fr) Agonistes de recepteur du facteur de croissance des hepatocytes et utilisation desdits agonistes
AU3878697A (en) Identification of abnormalities in the expression of t and cell antigen receptors as indicators of disease diagnosis, prognosis and therapeutic predictors
DE69433552D1 (de) An den zelloberflächenrezeptor hek bindendes cytokin
WO1999004265A8 (fr) Acides nucleiques et polypeptides associes au cancer
ATE177475T1 (de) Monoklonale antikörper gegen c-kit
CA2218452A1 (fr) Nouveaux ligands du recepteur neuropeptidique hfgan72
ATE368682T1 (de) Als 2f1 bezeichnetes rezeptorprotein
CA2284817A1 (fr) Procede permettant de determiner la presence d'une proteine brca issue de mutation
PL336470A1 (en) Mammalian cytokin-like factor 7
EP0672253A4 (fr) Antigene (sk1) associe au carcinome et anticorps monoclonaux diriges contre le sk1, procedes de production de ces anticorps et applications.
WO2000055629A3 (fr) Nouvelles techniques permettant de traiter et de diagnostiquer le cancer du sein, compositions et techniques de criblage pour modulateurs de cancer du sein
EP0163304A3 (fr) Anticorps monoclonaux humains contre des filaments intermédiaires
AU7075387A (en) Methods and compositions for the identification of metastatic human tumors
DE69719785D1 (de) Zusammensetzung aus brustkrebszellen, die mit einem gegen den rezeptor für insulin-ähnlichen wachstumsfaktor gerichteten antisens-oligonukleotidbehandelt worden sind.
CA2294476A1 (fr) Recepteurs de semaphorine
CA2207505A1 (fr) Moyens de criblage pour medicaments neurologiques
CA2106978A1 (fr) Compositions et methodes pour le traitement des cancers pulmonaires a petites cellules ou autres
SE9500030L (sv) Förfarande för bestämning av metastatisk potentialhos tumörceller
WO1998045442A3 (fr) Homologues de f-spondine secretee
EP1443055A3 (fr) Interleukines-21 et 22
EP0297930A3 (fr) Anticorps monoclonaux
WO2000039154A8 (fr) Peptides du recepteur at1 et son utilisation en cas de preeclampsie et d'hypertension maligne

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/20-20/20, DRAWINGS, REPLACED BY NEW PAGES 1/28-28/28; AFTER RECTIFICATION OF OBVIOUS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

WWE Wipo information: entry into national phase

Ref document number: 09583638

Country of ref document: US

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载